Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from InMed Pharmaceuticals (INM).
Dr. David G. Morgan, an esteemed expert in neurodegenerative disease, has joined the Scientific Advisory Board of a company, boosting their endeavors to develop their INM-901 program for Alzheimer’s treatment. This strategic addition underscores the company’s dedication to making significant strides in the fight against this challenging condition.
For detailed information about INM stock, go to TipRanks’ Stock Analysis page.